These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 31209573)

  • 1. Outcomes after fingolimod to alemtuzumab treatment shift in relapsing-remitting MS patients: a multicentre cohort study.
    Frau J; Saccà F; Signori A; Baroncini D; Fenu G; Annovazzi P; Capobianco M; Signoriello E; Laroni A; La Gioia S; Sartori A; Maniscalco GT; Bonavita S; Clerico M; Russo CV; Gallo A; Lapucci C; Carotenuto A; Sormani MP; Cocco E;
    J Neurol; 2019 Oct; 266(10):2440-2446. PubMed ID: 31209573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment with alemtuzumab or rituximab after fingolimod withdrawal in relapsing-remitting multiple sclerosis is effective and safe.
    Alcalá C; Gascón F; Pérez-Miralles F; Domínguez JA; Gil-Perotín S; Casanova B
    J Neurol; 2019 Mar; 266(3):726-734. PubMed ID: 30661133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switching from fingolimod to alemtuzumab in patients with highly active relapsing-remitting multiple sclerosis: Α case series.
    Notas K; Papadaki E; Orologas A; Moschou M; Kimiskidis VK
    Mult Scler Relat Disord; 2020 Feb; 38():101517. PubMed ID: 31751858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative analysis of fingolimod versus teriflunomide in relapsing-remitting multiple sclerosis.
    Boz C; Terzi M; Özer B; Turkoglu R; Karabudak R; Efendi H; Soysal A; Sevim S; Altintas A; Kurne A; Akçalı A; Akman G; Yüceyar N; Balcı BP; Ekmekci Ö; Karahan SZ; Demirkıran M; Altunrende B; Turan ÖF; Gökçen GözübatıkÇelik ; Kale N; Köseoğlu M; Ozakbas S
    Mult Scler Relat Disord; 2019 Nov; 36():101376. PubMed ID: 31473488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of alemtuzumab in a real-life cohort of patients with multiple sclerosis.
    Frau J; Coghe G; Lorefice L; Fenu G; Musu L; Cocco E
    J Neurol; 2019 Jun; 266(6):1405-1411. PubMed ID: 30863891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study.
    Kalincik T; Brown JWL; Robertson N; Willis M; Scolding N; Rice CM; Wilkins A; Pearson O; Ziemssen T; Hutchinson M; McGuigan C; Jokubaitis V; Spelman T; Horakova D; Havrdova E; Trojano M; Izquierdo G; Lugaresi A; Prat A; Girard M; Duquette P; Grammond P; Alroughani R; Pucci E; Sola P; Hupperts R; Lechner-Scott J; Terzi M; Van Pesch V; Rozsa C; Grand'Maison F; Boz C; Granella F; Slee M; Spitaleri D; Olascoaga J; Bergamaschi R; Verheul F; Vucic S; McCombe P; Hodgkinson S; Sanchez-Menoyo JL; Ampapa R; Simo M; Csepany T; Ramo C; Cristiano E; Barnett M; Butzkueven H; Coles A;
    Lancet Neurol; 2017 Apr; 16(4):271-281. PubMed ID: 28209331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing 'No Evidence of Disease Activity' Status in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Fingolimod in Routine Clinical Practice: A Retrospective Analysis of the Multiple Sclerosis Clinical and Magnetic Resonance Imaging Outcomes in the USA (MS-MRIUS) Study.
    Weinstock-Guttman B; Medin J; Khan N; Korn JR; Lathi E; Silversteen J; Calkwood J; Silva D; Zivadinov R;
    CNS Drugs; 2018 Jan; 32(1):75-84. PubMed ID: 29270772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alemtuzumab as rescue therapy in a cohort of 50 relapsing-remitting MS patients with breakthrough disease on fingolimod: a multi-center observational study.
    Huhn K; Bayas A; Doerck S; Frank B; Gerbershagen K; Hellwig K; Kallmann B; Kleinschnitz C; Kleiter I; Lee DH; Limmroth V; Mäurer M; Meuth S; Rieckmann P; Ruck T; Gold R; Linker RA
    J Neurol; 2018 Jul; 265(7):1521-1527. PubMed ID: 29696498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What happens after fingolimod discontinuation? A multicentre real-life experience.
    Landi D; Signori A; Cellerino M; Fenu G; Nicoletti CG; Ponzano M; Mancuso E; Fronza M; Ricchiuto ME; Boffa G; Inglese M; Marfia GA; Cocco E; Frau J
    J Neurol; 2022 Feb; 269(2):796-804. PubMed ID: 34136943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study.
    Ziemssen T; Bass AD; Berkovich R; Comi G; Eichau S; Hobart J; Hunter SF; LaGanke C; Limmroth V; Pelletier D; Pozzilli C; Schippling S; Sousa L; Traboulsee A; Uitdehaag BMJ; Van Wijmeersch B; Choudhry Z; Daizadeh N; Singer BA;
    CNS Drugs; 2020 Sep; 34(9):973-988. PubMed ID: 32710396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early initiation of fingolimod reduces the rate of severe relapses over the long term: Post hoc analysis from the FREEDOMS, FREEDOMS II, and TRANSFORMS studies.
    Haas J; Jeffery D; Silva D; Meier DP; Meinert R; Cohen J; Hartung HP
    Mult Scler Relat Disord; 2019 Nov; 36():101335. PubMed ID: 31557679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fingolimod reduces the clinical expression of active demyelinating lesions in MS.
    Signoriello E; Landi D; Monteleone F; Saccà F; Nicoletti CG; Buttari F; Sica F; Marfia GA; Di Iorio G; Lus G; Centonze D
    Mult Scler Relat Disord; 2018 Feb; 20():215-219. PubMed ID: 29433094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis.
    Roos I; Sharmin S; Malpas C; Ozakbas S; Lechner-Scott J; Hodgkinson S; Alroughani R; Eichau Madueño S; Boz C; van der Walt A; Butzkueven H; Buzzard K; Skibina O; Foschi M; Grand'Maison F; John N; Grammond P; Terzi M; Prévost J; Barnett M; Laureys G; Van Hijfte L; Luis Sanchez-Menoyo J; Blanco Y; Oh J; McCombe P; Ramo Tello C; Soysal A; Prat A; Duquette P; Yamout BI; Khoury S; van Pesch V; Macdonell R; José Sá M; Slee M; Kuhle J; Maimone D; Spitaleri D; Willekens B; Asmi AA; Tallantyre E; Robertson NP; Coles A; L Brown JW; Kalincik T
    Mult Scler; 2024 Aug; 30(9):1163-1175. PubMed ID: 39087208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The real-world effectiveness and safety of fingolimod in relapsing-remitting multiple sclerosis patients: An observational study.
    Izquierdo G; Damas F; Páramo MD; Ruiz-Peña JL; Navarro G
    PLoS One; 2017; 12(4):e0176174. PubMed ID: 28453541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment.
    Vollmer BL; Nair K; Sillau S; Corboy JR; Vollmer T; Alvarez E
    Ann Clin Transl Neurol; 2020 Sep; 7(9):1466-1476. PubMed ID: 32767538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retrospectively acquired cohort study to evaluate the long-term impact of two different treatment strategies on disability outcomes in patients with relapsing multiple sclerosis (RE.LO.DI.MS): data from the Italian MS Register.
    Paolicelli D; Lucisano G; Manni A; Avolio C; Bonavita S; Brescia Morra V; Capobianco M; Cocco E; Conte A; De Luca G; De Robertis F; Gasperini C; Gatto M; Gazzola P; Lus G; Iaffaldano A; Iaffaldano P; Maimone D; Mallucci G; Maniscalco GT; Marfia GA; Patti F; Pesci I; Pozzilli C; Rovaris M; Salemi G; Salvetti M; Spitaleri D; Totaro R; Zaffaroni M; Comi G; Amato MP; Trojano M;
    J Neurol; 2019 Dec; 266(12):3098-3107. PubMed ID: 31535270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relapses in patients treated with fingolimod after previous exposure to natalizumab.
    Comi G; Gold R; Dahlke F; Sinha A; von Rosenstiel P; Tomic D; Kappos L
    Mult Scler; 2015 May; 21(6):786-90. PubMed ID: 25257618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-utility analysis of alemtuzumab in comparison with interferon beta, fingolimod, and natalizumab treatment for relapsing-remitting multiple sclerosis in Austria.
    Walter E; Berger T; Bajer-Kornek B; Deisenhammer F
    J Med Econ; 2019 Mar; 22(3):226-237. PubMed ID: 30522373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alemtuzumab significantly improves posterior fossa syndrome presented as a relapse of multiple sclerosis.
    Signoriello E; D'Amico A; Fratta M; Ugga L; Altobelli C; Conchiglia G; Barbarulo AM; Di Pietro A; Anastasio P; Rossi F; Lus G
    Mult Scler Relat Disord; 2020 Feb; 38():101518. PubMed ID: 31778927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lateral switch to IFN beta-1a 44 mcg may be effective as escalation switch to fingolimod in selected persons with relapsing remitting multiple sclerosis: a real-world setting experience.
    D'Amico E; Patti F; Zanghì A; Lo Fermo S; Chisari CG; Zappia M
    Expert Rev Clin Pharmacol; 2018 May; 11(5):531-536. PubMed ID: 29521113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.